Evaluation of omadacycline against intracellular Mycobacterium abscessus in an infection model in human macrophages.

ABSTRACT:

Background

Omadacycline is an aminomethylcycline antibiotic in the tetracycline class that was approved by the US FDA in 2018 for the treatment of community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections. It is available in both IV and oral formulations. Omadacycline has broad-spectrum in vitro activity and clinical efficacy against infections caused by Gram-positive and Gram-negative pathogens. Omadacycline is being evaluated in a 3 month placebo-controlled Phase 2 clinical trial of oral omadacycline versus placebo in adults with non-tuberculous mycobacteria (NTM) pulmonary disease caused by Mycobacterium abscessus (NCT04922554).

Objectives

To determine if omadacycline has intracellular antimicrobial activity against NTM, b

SUBMITTER: Jahanbakhsh S 

PROVIDER: S-EPMC10502775 | biostudies-literature | 2023 Oct

REPOSITORIES: biostudies-literature